Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF

OBJECTIVE: The use of alemtuzumab, a humanized monoclonal anti-CD52 antibody has changed the therapy of highly active relapsing-remitting MS (RRMS). Alemtuzumab infusion depletes most lymphocytes in peripheral blood, whereas differential recovery of immune cells, probably those with a less CNS-autor...

Descripción completa

Detalles Bibliográficos
Autores principales: Möhn, Nora, Pfeuffer, Steffen, Ruck, Tobias, Gross, Catharina C., Skripuletz, Thomas, Klotz, Luisa, Wiendl, Heinz, Stangel, Martin, Meuth, Sven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007635/
https://www.ncbi.nlm.nih.gov/pubmed/31826986
http://dx.doi.org/10.1212/NXI.0000000000000654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007635/
https://www.ncbi.nlm.nih.gov/pubmed/31826986
http://dx.doi.org/10.1212/NXI.0000000000000654

Ejemplares similares